LPOXY initiates $28M Series A financing with 5 Horizons Ventures to fund pivotal trial
September 4, 2025 | Startland News Staff
PLATTE CITY, Mo. — Funding to secure the upcoming trial of a Missouri biopharmaceutical company’s solution for preventing a deadly gut infection could prove critical in the fight against a condition that claims 80 U.S. lives daily, said Dr. Larry Sutton.
LPOXY Therapeutics, which is developing a novel non-antibiotic therapy to prevent Clostridioides difficile infections (Cdiff), announced Wednesday it has signed a term sheet with 5Horizons Ventures, a life science venture capital firm focused on innovative healthcare solutions in support of a $28 million Series A financing.
Elevator pitch: LPOXY Therapeutics is transforming infection prevention with a first-in-class oral therapeutic aimed at preventing C. difficile colitis, a CDC-designated urgent public health threat that kills over 80 Americans every day. Our unique approach delivers oxygen directly to the gut, creating an environment hostile to C. difficile bacteria without using antibiotics.
The agreement facilitates the formation of an investment syndicate to fund LPOXY’s registrational STOP-Cdiff (SIDIPREV Trial On Prevention of C. difficile Infections) clinical trial.
“5 Horizons Ventures’ commitment marks a major milestone for LPOXY as we move toward launching our pivotal STOP-Cdiff trial,” said Sutton, CEO and co-founder of LPOXY, one of Startland News’ 10 Kansas City Startups to Watch in 2025. “SIDIPREV represents a novel approach to infection prevention that not only addresses a deadly unmet need but also aligns with hospital economics by reducing costly complications within fixed DRG payments.”
ICYMI: LPOXY Therapeutics punches back at gut infection (and a foe with a billion-year head start)
The upcoming trial is designed under the FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs guidance and is intended to serve as the registrational study for SIDIPREV™, a therapy that aims to prevent life-threatening Cdiff in high-risk hospitalized patients. C. difficile is categorized by the CDC as an urgent public health threat that kills 80 Americans every day.
SIDIPREV is an orally administered, enteric-coated capsule that releases a metered dose of oxygen into the lower gastrointestinal tract, creating an environment hostile to anaerobic pathogens like C. difficile. Oxygen also suppresses toxin production and has mucosal anti-inflammatory effects.
As planned, STOP-Cdiff is a randomized, placebo-controlled superiority trial that will evaluate the efficacy and safety of SIDIPREV in approximately 500 hospitalized patients at elevated risk for Cdiff due to age and antibiotic exposure. LPOXY aims to launch the trial in Q3 2026 and file for approval in 2029.
“We’re impressed by the LPOXY team, their data, and their clear-eyed strategy for succeeding where many anti-infective programs have struggled,” said Paul Ferguson, partner and CFO of 5 Horizons Ventures. “SIDIPREV avoids the reimbursement and resistance-related hurdles that have plagued traditional antibiotics, making this a rare opportunity to unlock real economic value for patients, hospitals, and investors.”
LPOXY is actively building its investment syndicate and is in discussions with other institutional investors aligned with its late-stage clinical strategy.
2025 Startups to Watch
stats here
Related Posts on Startland News
Artist incubator paints scene of blissful collaboration in far-from-lonely West Bottoms space
Vanessa Lacy’s artist incubator eliminates “the lonely artist,” she said, noting her gallery model replaces solitude with creative relationships and a collaborative community. “Artists tend to get very isolated in their studio spaces working on their own; then they have a relationship with a gallery that’s really more of a business relationship,” said Lacy, owner…
Order here: Menufy online restaurant platform delivers results, food from OP startup
Servicing the online orders of more than 300 restaurants in the Kansas City metro, Overland Park-based Menufy is scaling its platform across the U.S., while maintaining a startup mindset, said Ashishh Desai. “Even though now we have over 4,000 restaurants nationwide — every state but Vermont and in 1,200 cities — we still have that…
Take the Kauffman survey: Is KC’s startup culture welcoming and inclusive to all?
Perception shapes reality, said organizers of a survey that seeks greater understanding of Kansas City’s startup culture. The Ewing Marion Kauffman Foundation’s 2018 Entrepreneurship in Kansas City survey checks the pulse of the local entrepreneurial ecosystem by raising specific questions about culture and practice in workplaces across the metro, said John Quinterno and Julie Marks,…
Onward scores $1M grant from Chan Zuckerberg Initiative for payday loan end-run
Everyone needs a financial cushion, said Ronnie Washington — even a fintech startup offering low- to moderate-income workers a path to avoid predatory lending practices, the Onward founder said. A member of KC-based Fountain City Fintech’s inaugural cohort, Onward is one of 10 companies from across the U.S. and Puerto Rico being awarded $1 million…